<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Famciclovir: An overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Famciclovir: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Famciclovir: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">Famciclovir</a> is an oral prodrug that is converted by first-pass metabolism to the antiviral drug <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a> [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">Penciclovir</a>, upon intracellular uptake, is monophosphorylated by virally-encoded thymidine kinase and subsequently converted to a triphosphate by cellular enzymes. Penciclovir triphosphate preferentially inhibits the DNA polymerase of susceptible viruses; at clinically relevant levels, there is no substantial effect upon cellular DNA polymerase, thereby minimizing side effects to the host [<a href="#rid2">2</a>].</p><p>This mechanism is similar to that described for <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>; however, compared with acyclovir triphosphate, <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a> triphosphate has a lower affinity for viral DNA polymerase but a longer intracellular half-life [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">"Acyclovir: An overview"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Spectrum of activity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">Penciclovir</a> is active against herpes simplex virus (HSV) types 1 and 2, and varicella zoster virus (VZV). Epstein-Barr virus is also susceptible in vitro [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Mechanism of resistance</span><span class="headingEndMark"> — </span>The mechanisms of resistance to <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a> are similar to those described for <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> [<a href="#rid3">3</a>]. Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced or absent thymidine kinase</p><p class="bulletIndent1"><span class="glyph">●</span>Altered thymidine kinase activity resulting in decreased <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> phosphorylation</p><p class="bulletIndent1"><span class="glyph">●</span>Altered viral DNA polymerase with decreased affinity for <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> triphosphate</p><p></p><p>(See  <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">"Acyclovir: An overview", section on 'Mechanism of resistance'</a>.)</p><p>Most acyclovir-resistant strains of HSV and VZV exhibit cross-resistance to <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a>; reduced or absent viral thymidine kinase is the primary mechanism [<a href="#rid2">2,5</a>]. However, some acyclovir-resistant and foscarnet-resistant isolates remain susceptible to penciclovir. These strains demonstrate altered thymidine kinase and DNA polymerase substrate specificity [<a href="#rid2">2,5,6</a>].</p><p class="headingAnchor" id="H5"><span class="h1">BASIC PHARMACOKINETICS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">Famciclovir</a> is well absorbed, featuring an oral bioavailability of 77 percent [<a href="#rid7">7</a>]. Prompt first-pass metabolism in the intestine and liver results in conversion to <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a>. A 500 mg dose of famciclovir yields peak penciclovir levels of 2.7 to 4 mg/L, with a plasma half-life of 2.1 to 2.7 hours. Food has no clinically important effect upon these levels [<a href="#rid2">2</a>].</p><p>A key feature of <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a> is a prolonged intracellular half-life of penciclovir triphosphate: 10 to 20 hours in herpes simplex virus-infected cells, and 7 to 14 hours in varicella zoster virus-infected cells. In comparison, the intracellular half-life of <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> triphosphate is one hour or less [<a href="#rid2">2</a>]. As a result, <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">famciclovir</a> requires less frequent dosing.</p><p>Excretion is primarily renal, and dose reduction is recommended in patients with impaired renal function (creatinine clearance under 60 mL/min) [<a href="#rid1">1,2</a>]. <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">Penciclovir</a> is removed by hemodialysis [<a href="#rid1">1</a>]. Well-compensated chronic liver disease does not require dose modification, but pharmacokinetic studies in patients with poorly compensated hepatic insufficiency have not been performed [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H6"><span class="h1">TOXICITY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">Famciclovir</a> is very well tolerated, with a side effect profile similar to those of placebo and oral <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>, although long-term safety data are unavailable [<a href="#rid1">1</a>] (see  <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">"Acyclovir: An overview"</a>). A review of over 1600 patients receiving famciclovir for herpes zoster or genital herpes revealed an adverse event profile not significantly different from placebo [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H7"><span class="h1">USE IN PREGNANCY</span><span class="headingEndMark"> — </span>Available data from pharmacovigilance reports have found no association between <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">famciclovir</a> and increased risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies also suggest safety. In order to monitor the outcomes of pregnancies exposed to this drug, providers are encouraged to report cases to the Novartis Adverse Event reporting line at 1-888-NOW-NOVA (669-6682) [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H1303734295"><span class="h1">USE DURING BREASTFEEDING</span><span class="headingEndMark"> — </span>Animal studies show that <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a> is present in the milk of lactating rats. However, no data are available regarding the presence of <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">famciclovir</a> or penciclovir in human breast milk, the impact of these drugs on milk production, or the safety of breastfed infants if the mother is taking famciclovir. Thus, the decision to use famciclovir in mothers who are breastfeeding must balance the benefits of breastfeeding with the mother's clinical need for famciclovir and the potential (albeit unknown) adverse effects on the breastfed infant [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H8"><span class="h1">USE OF FAMCICLOVIR IN IMMUNOCOMPETENT PATIENTS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">Famciclovir</a> is one possible treatment option for patients with acute herpes zoster [<a href="#rid10">10,11</a>] and those with primary and recurrent genital herpes infection [<a href="#rid12">12-14</a>]. The management and treatment of these infections is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8293.html" rel="external">"Treatment of herpes zoster"</a> and  <a class="medical medical_review" href="/z/d/html/8346.html" rel="external">"Treatment of genital herpes simplex virus infection"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">USE OF FAMCICLOVIR IN IMMUNOCOMPROMISED PATIENTS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">Famciclovir</a> is one potential treatment option for herpes zoster and primary and recurrent genital herpes in immunocompromised patients [<a href="#rid14">14-16</a>]. The approach to the treatment of genital herpes infections in the HIV-infected host is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16701.html" rel="external">"Treatment of drug-resistant genital herpes simplex virus infection in patients with HIV"</a>.)</p><p class="headingAnchor" id="H1414793"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">Famciclovir</a> is an oral prodrug which is converted by first-pass metabolism to the antiviral drug <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a>. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upon intracellular uptake, <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a> is mono-phosphorylated by virally-encoded thymidine kinase and subsequently converted to a triphosphate by cellular enzymes. Penciclovir triphosphate preferentially inhibits the DNA polymerase of susceptible viruses. At clinically relevant levels, there is no substantial effect upon cellular DNA polymerase, thereby minimizing side effects to the host. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">Penciclovir</a> is active against herpes simplex virus (HSV) types 1 and 2, and varicella-zoster virus (VZV). (See <a class="local">'Spectrum of activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mechanisms of resistance to <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a> are similar to those described for <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>. Most acyclovir-resistant strains of HSV and VZV exhibit cross-resistance to penciclovir. Resistance is rarely seen among immunocompetent hosts but has been well-documented in immunocompromised hosts, such as transplant recipients and HIV-infected patients. (See <a class="local">'Mechanism of resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A key feature of <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">penciclovir</a> is a prolonged intracellular half-life of penciclovir triphosphate: 10 to 20 hours in HSV-infected cells, and 7 to 14 hours in VZV-infected cells. In comparison, the intracellular half-life of <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> triphosphate is one hour or less. As a result, <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">famciclovir</a> requires less frequent dosing. (See <a class="local">'Basic pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excretion is primarily renal, and dose reduction is recommended in patients with impaired renal function (creatinine clearance under 60 mL/min). (See <a class="local">'Basic pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">Famciclovir</a> is very well tolerated, with a side effect profile similar to that of placebo, although long-term safety data are unavailable. (See <a class="local">'Toxicity'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Famvir (famciclovir) prescribing information. SmithKline Beecham, 1997.</li><li><a class="nounderline abstract_t">Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995; 50:396.</a></li><li><a class="nounderline abstract_t">Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.</a></li><li><a class="nounderline abstract_t">Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.</a></li><li><a class="nounderline abstract_t">Boyd MR, Safrin S, Kern ER. Penciclovir: A review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother 1993; 4(Suppl 1):3.</a></li><li><a class="nounderline abstract_t">Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother 1993; 37:2241.</a></li><li><a class="nounderline abstract_t">Vere Hodge RA. Famciclovir and penciclovir: The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 1993; 4:67.</a></li><li><a class="nounderline abstract_t">Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994; 38:2454.</a></li><li class="breakAll">US Food and Drug Administration. Highlights of prescribing information: Famvir (famciclovir). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf (Accessed on March 25, 2019).</li><li><a class="nounderline abstract_t">Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123:89.</a></li><li><a class="nounderline abstract_t">Boon RJ, Griffin DR. Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Neurology 1995; 45:S76.</a></li><li><a class="nounderline abstract_t">Loveless M, Sacks SL, Harris JRW. Famciclovir in the management of first-episode genital herpes. IDCP 1997; 6:S12.</a></li><li><a class="nounderline abstract_t">Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996; 276:44.</a></li><li><a class="nounderline abstract_t">Sacks SL. Management of recurrent genital herpes — episodic therapy with famciclovir. IDCP 1997; 6:S5.</a></li><li><a class="nounderline abstract_t">Frechette G, Romanowski B. Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients. Can J Infect Dis 1997; 8:44A.</a></li><li><a class="nounderline abstract_t">Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:21.</a></li></ol></div><div id="topicVersionRevision">Topic 8338 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Famvir (famciclovir) prescribing information. SmithKline Beecham, 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8521764" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565338" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Drugs for non-HIV viral infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416838" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Resistance of herpesviruses to antiviral drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Penciclovir: A review of its spectrum of activity, selectivity, and cross-resistance pattern</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8257152" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Famciclovir and penciclovir: The mode of action of famciclovir including its conversion to penciclovir</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7840587" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Safety of famciclovir in patients with herpes zoster and genital herpes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7840587" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Safety of famciclovir in patients with herpes zoster and genital herpes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7778840" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8545031" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Famciclovir in the management of first-episode genital herpes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8667538" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Management of recurrent genital herpes—episodic therapy with famciclovir</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9424977" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
